Cyclacel's cyc065 and venetoclax demonstrate therapeutic potential and anticancer activity

Cyclacel's cyc065 and venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias.cyclacel pharmaceuticals inc - cyc065-venetoclax combination was well tolerated and no dose-limiting toxicities have been reported.cyclacel pharmaceuticals inc - in cyc065-venetoclax study no tumor lysis syndrome was observed.cyclacel pharmaceuticals - combination of cyc065 and venetoclax has demonstrated preclinical synergy in both aml and cll models.cyclacel pharmaceuticals inc - in aml/mds upregulation of mcl1 is associated with resistance to chemotherapy and/or venetoclax.
CYCC Ratings Summary
CYCC Quant Ranking